Cargando…
Ruxolitinib as an Effective Treatment for Hemophagocytic Lymphohistiocytosis Secondary to SARS-Cov-2 Infection: A Case Report
BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome. SARS-CoV-2 infection can induce secondary HLH, as described in previous case reports, but diagnosis and treatment are challenging. CASE STUDY: We described an older male patient diagnosed with HLH...
Autores principales: | Wang, Lina, Zhang, Xiaolin, Huang, Bo, Hou, Yue, Liu, Xinmin, Jiao, Hongmei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149062/ https://www.ncbi.nlm.nih.gov/pubmed/37131454 http://dx.doi.org/10.2147/IDR.S384035 |
Ejemplares similares
-
Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023) -
Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS
por: Liu, Xiang, et al.
Publicado: (2022) -
Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
por: Keenan, Camille, et al.
Publicado: (2021) -
Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis
por: Chi, Ying, et al.
Publicado: (2021) -
Secondary Hemophagocytic Lymphohistiocytosis in a Neonate with SARS-CoV-2 Infection
por: El-Isa, Hasan Zuhair, et al.
Publicado: (2022)